Cargando…

Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic

Detalles Bibliográficos
Autores principales:	Margoni, Monica, Gallo, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556166/ https://www.ncbi.nlm.nih.gov/pubmed/33110621 http://dx.doi.org/10.1177/2055217320966346

Ejemplares similares

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2023)

Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection
por: Landi, Doriana, et al.
Publicado: (2022)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
por: Sood, Arjun B., et al.
Publicado: (2016)

Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities
por: Margoni, Monica, et al.
Publicado: (2021)

Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
por: Capuano, Rocco, et al.
Publicado: (2021)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Treatment with natalizumab during the Covid-19 pandemic in multiple sclerosis patients
por: Díaz-Díaz, Judit, et al.
Publicado: (2021)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients
por: Verkkoniemi-Ahola, Auli, et al.
Publicado: (2023)

The unexpected finding of a hemangioblastoma on the cerebellum of a patient undergoing treatment with natalizumab for multiple sclerosis
por: Fragoso, Yara Dadalti, et al.
Publicado: (2017)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Progress in the Management of Paediatric-Onset Multiple Sclerosis
por: Luchesa Smith, Aphra, et al.
Publicado: (2020)

Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
por: Chisari, Clara G., et al.
Publicado: (2021)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
por: Planas, Raquel, et al.
Publicado: (2014)

Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients
por: Tanaka, Masami, et al.
Publicado: (2016)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Disrupted balance of T cells under natalizumab treatment in multiple sclerosis
por: Kimura, Kimitoshi, et al.
Publicado: (2016)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
por: Maier, Smaranda, et al.
Publicado: (2020)

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
por: Kim, Ki Hoon, et al.
Publicado: (2021)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0kds0k63o88cq1omhvahqj0i7p